Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
2000 1
2003 1
2004 2
2005 1
2007 6
2008 4
2009 5
2010 4
2011 8
2012 7
2013 15
2014 14
2015 9
2016 10
2017 9
2018 6
2019 9
2020 2
Text availability
Article attribute
Article type
Publication date

Similar Articles for PMID: 32276945

98 results
Results by year
Filters applied: . Clear all
Page 1
Fibroblast Growth Factor 23 and the Last Mile.
Gutiérrez OM. Gutiérrez OM. Clin J Am Soc Nephrol. 2020 Apr 10:CJN.13631119. doi: 10.2215/CJN.13631119. Online ahead of print. Clin J Am Soc Nephrol. 2020. PMID: 32276945 No abstract available.
Mineral metabolism in heart disease.
Heine GH. Heine GH. Curr Opin Nephrol Hypertens. 2015 Jul;24(4):310-6. doi: 10.1097/MNH.0000000000000129. Curr Opin Nephrol Hypertens. 2015. PMID: 26050116 Review.
Serum FGF23 and risk of cardiovascular events in relation to mineral metabolism and cardiovascular pathology.
Ärnlöv J, Carlsson AC, Sundström J, Ingelsson E, Larsson A, Lind L, Larsson TE. Ärnlöv J, et al. Clin J Am Soc Nephrol. 2013 May;8(5):781-6. doi: 10.2215/CJN.09570912. Epub 2013 Jan 18. Clin J Am Soc Nephrol. 2013. PMID: 23335040 Free PMC article.
The use of fibroblast growth factor 23 testing in patients with kidney disease.
Smith ER. Smith ER. Clin J Am Soc Nephrol. 2014 Jul;9(7):1283-303. doi: 10.2215/CJN.10941013. Epub 2014 Feb 27. Clin J Am Soc Nephrol. 2014. PMID: 24578336 Free PMC article. Review.
Fibroblast growth factor 23 as a phosphotropic hormone and beyond.
Fukumoto S, Shimizu Y. Fukumoto S, et al. J Bone Miner Metab. 2011 Sep;29(5):507-14. doi: 10.1007/s00774-011-0298-0. Epub 2011 Aug 6. J Bone Miner Metab. 2011. PMID: 21822586 Review.
Chronic Hyperphosphatemia and Vascular Calcification Are Reduced by Stable Delivery of Soluble Klotho.
Hum JM, O'Bryan LM, Tatiparthi AK, Cass TA, Clinkenbeard EL, Cramer MS, Bhaskaran M, Johnson RL, Wilson JM, Smith RC, White KE. Hum JM, et al. J Am Soc Nephrol. 2017 Apr;28(4):1162-1174. doi: 10.1681/ASN.2015111266. Epub 2016 Nov 11. J Am Soc Nephrol. 2017. PMID: 27837149 Free PMC article.
Phosphate Metabolism in Cardiorenal Metabolic Disease.
Gupta D, Brietzke S, Hayden MR, Kurukulasuriya LR, Sowers JR. Gupta D, et al. Cardiorenal Med. 2011;1(4):261-270. doi: 10.1159/000332388. Epub 2011 Oct 13. Cardiorenal Med. 2011. PMID: 22096458 Free PMC article.
Safety and efficacy evaluation of lanthanum carbonate for hyperphosphatemia in end-stage renal disease patients.
Shigematsu T, Ohya M, Negi S, Masumoto AR, Nakashima YM, Iwatani Y, Moribata MK, Yamanaka S, Tatsuta K, Mima T. Shigematsu T, et al. Contrib Nephrol. 2015;185:42-55. doi: 10.1159/000380969. Epub 2015 May 19. Contrib Nephrol. 2015. PMID: 26023014
Ablation of the Galnt3 gene leads to low-circulating intact fibroblast growth factor 23 (Fgf23) concentrations and hyperphosphatemia despite increased Fgf23 expression.
Ichikawa S, Sorenson AH, Austin AM, Mackenzie DS, Fritz TA, Moh A, Hui SL, Econs MJ. Ichikawa S, et al. Endocrinology. 2009 Jun;150(6):2543-50. doi: 10.1210/en.2008-0877. Epub 2009 Feb 12. Endocrinology. 2009. PMID: 19213845 Free PMC article.
98 results
Jump to page
Feedback